RE:Dr. Kamat Speaks with ImmunityBio's Dr. Soon-ShiongSo that's the good news because it's an immunological stimulant. What I'm really excited about is the potential that the Serum Institute's next generation recombinant BCG is even more potent, more immunogenic, and even, according to them from the phase two data in Europe, safer than the current BCG. So yes, I think the combination of the synergistic effect of the BCG giving you the CD4, CD8 T cells, and then our Anktiva proliferating that as well as giving NK cells, is really, really exciting as this next immunotherapy generation for bladder cancer.